Intellia Therapeutics Presents New Data From Its Engineered Cell Therapy and In Vivo Programs at Keystone Symposia’s Engineering the Genome Conference
Intellia Therapeutics, Inc. (NTLA)
Last intellia therapeutics, inc. earnings: 2/27 07:30 am
Check Earnings Report
US:NASDAQ Investor Relations:
ir.intelliatx.com/investor-overview
Company Research
Source: GlobeNewswire
Specific and potent tumor cell killing observed in WT1-positive acute myeloid leukemia blasts in vitro by TCR-based engineered T cells, supporting Intellia’s first engineered T cell therapy development candidate, NTLA-5001Knockout of KLKB1 gene with CRISPR/Cas9 for hereditary angioedema results in therapeutically relevant reduction of kallikrein activity sustained for five months of observation in an ongoing non-human primate study CAMBRIDGE, Mass., Feb. 10, 2020 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on developing curative therapeutics using CRISPR/Cas9 technology both in vivo and ex vivo, is presenting new data from two of its development programs at Keystone Symposia’s Engineering the Genome Conference, a joint meeting with the Emerging Cellular Therapies: Cancer and Beyond Conference, taking place Feb. 8-12, 2020, in Banff, Canada. Intellia researchers are presenting data in support of the company’s lead engineere
Show less
Read more
Impact Snapshot
Event Time:
NTLA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NTLA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NTLA alerts
High impacting Intellia Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
NTLA
News
- Intellia Therapeutics, Inc. (NASDAQ: NTLA) had its price target lowered by analysts at Oppenheimer Holdings Inc. from $70.00 to $60.00. They now have an "outperform" rating on the stock.MarketBeat
- Intellia Therapeutics, Inc. (NASDAQ:NTLA) Just Reported Third-Quarter Earnings And Analysts Are Lifting Their Estimates [Yahoo! Finance]Yahoo! Finance
- Intellia Therapeutics, Inc. (NASDAQ: NTLA) was upgraded by analysts at StockNews.com to a "sell" rating.MarketBeat
- Intellia Therapeutics, Inc. (NASDAQ: NTLA) had its price target lowered by analysts at Barclays PLC from $76.00 to $55.00. They now have an "overweight" rating on the stock.MarketBeat
- Intellia Therapeutics Inc (NTLA) Q3 2024 Earnings Call Highlights: Financial Stability and ... [Yahoo! Finance]Yahoo! Finance
NTLA
Earnings
- 11/7/24 - Beat
NTLA
Sec Filings
- 11/7/24 - Form 10-Q
- 11/7/24 - Form 8-K
- 10/25/24 - Form 8-K
- NTLA's page on the SEC website